Facebook Com (FB) Market Valuation Rose While Harvey Capital Management Has Cut Its Stake by $954,550; Kazazian Asset Management Increases Holding in Aurinia Pharmaceuticals (AUPH)

January 14, 2018 - By Hazel Jackson

Kazazian Asset Management Llc increased its stake in Aurinia Pharmaceuticals Inc (AUPH) by 111.05% based on its latest 2017Q3 regulatory filing with the SEC. Kazazian Asset Management Llc bought 73,633 shares as the company’s stock rose 92.23% with the market. The institutional investor held 139,937 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $877,000, up from 66,304 at the end of the previous reported quarter. Kazazian Asset Management Llc who had been investing in Aurinia Pharmaceuticals Inc for a number of months, seems to be bullish on the $442.65 million market cap company. The stock increased 1.71% or $0.09 during the last trading session, reaching $5.35. About 1.04M shares traded. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has risen 200.00% since January 14, 2017 and is uptrending. It has outperformed by 183.30% the S&P500.

Harvey Capital Management Inc decreased its stake in Facebook Inc Com (FB) by 13.76% based on its latest 2017Q3 regulatory filing with the SEC. Harvey Capital Management Inc sold 5,615 shares as the company’s stock rose 10.88% with the market. The institutional investor held 35,185 shares of the technology company at the end of 2017Q3, valued at $6.01M, down from 40,800 at the end of the previous reported quarter. Harvey Capital Management Inc who had been investing in Facebook Inc Com for a number of months, seems to be less bullish one the $521.22 billion market cap company. The stock decreased 4.47% or $8.4 during the last trading session, reaching $179.37. About 77.55M shares traded or 356.22% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since January 14, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Among 5 analysts covering Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals Inc had 11 analyst reports since June 30, 2016 according to SRatingsIntel. Canaccord Genuity downgraded the shares of AUPH in report on Wednesday, September 13 to “Speculative Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $1400 target in Monday, June 5 report. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, October 23 report. As per Thursday, June 30, the company rating was initiated by H.C. Wainwright. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has “Buy” rating given on Tuesday, October 24 by Canaccord Genuity. The firm has “Overweight” rating by Cantor Fitzgerald given on Tuesday, April 11. Leerink Swann maintained the shares of AUPH in report on Monday, October 23 with “Outperform” rating. The rating was maintained by H.C. Wainwright with “Buy” on Friday, December 30. The rating was maintained by Cantor Fitzgerald on Friday, August 11 with “Buy”.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on February, 7. They expect $1.94 EPS, up 56.45% or $0.70 from last year’s $1.24 per share. FB’s profit will be $5.64 billion for 23.11 P/E if the $1.94 EPS becomes a reality. After $1.59 actual EPS reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 22.01% EPS growth.

Investors sentiment decreased to 1.15 in Q3 2017. Its down 0.25, from 1.4 in 2017Q2. It turned negative, as 53 investors sold FB shares while 618 reduced holdings. 128 funds opened positions while 644 raised stakes. 1.63 billion shares or 0.88% more from 1.62 billion shares in 2017Q2 were reported. Northeast Inv Mngmt reported 210,639 shares stake. Mariner Wealth Advsrs Limited Liability Company stated it has 0.24% in Facebook, Inc. (NASDAQ:FB). Sg Americas reported 81,616 shares. Dillon & Assocs reported 1.75% in Facebook, Inc. (NASDAQ:FB). California-based Assetmark has invested 0.18% in Facebook, Inc. (NASDAQ:FB). Washington-based Cornerstone Advsrs has invested 0.55% in Facebook, Inc. (NASDAQ:FB). Howe And Rusling holds 1.2% in Facebook, Inc. (NASDAQ:FB) or 37,821 shares. Kemper Corporation Master Retirement Tru, Illinois-based fund reported 39,900 shares. Coatue Management Limited Liability Company reported 9.22% in Facebook, Inc. (NASDAQ:FB). Artisan Prtnrs Lp has invested 1.14% in Facebook, Inc. (NASDAQ:FB). Sentinel Asset Mngmt invested in 0.43% or 104,700 shares. Chesley Taft And Assocs Lc reported 2.09% stake. Renaissance Ltd Liability Co invested in 470,500 shares. Guardian Life Insurance Of America accumulated 5,395 shares. Wealthtrust Axiom Llc reported 2,562 shares.

Among 53 analysts covering Facebook (NASDAQ:FB), 49 have Buy rating, 2 Sell and 2 Hold. Therefore 92% are positive. Facebook had 217 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, November 5 by Canaccord Genuity. Mizuho maintained the stock with “Buy” rating in Thursday, November 3 report. As per Thursday, November 5, the company rating was maintained by Barclays Capital. The firm has “Buy” rating by Canaccord Genuity given on Thursday, April 28. Piper Jaffray maintained Facebook, Inc. (NASDAQ:FB) rating on Tuesday, August 18. Piper Jaffray has “Overweight” rating and $146 target. The company was maintained on Thursday, July 27 by Pivotal Research. The firm has “Buy” rating given on Thursday, December 1 by Canaccord Genuity. Bank of America maintained the shares of FB in report on Monday, July 24 with “Buy” rating. Cowen & Co maintained it with “Buy” rating and $200.0 target in Wednesday, September 27 report. The firm earned “Buy” rating on Wednesday, October 11 by RBC Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: